Current cost savings alone from infliximab biosimilars are “insufficient to promote their widespread use” in the United States, and comparable savings to those achieved in some European companies may not be possible without systemic reform of the U.S. pharmaceutical market, according to findings published in Arthritis & Rheumatology.

“Currently in the United States, other TNF inhibitor biosimilars — such as those for adalimumab or etanercept — are not available despite many of them being FDA approved,” Seoyoung C. Kim, MD, ScD, MSCE, of Harvard Medical School and Brigham and Women's Hospital, told Healio Rheumatology. “Our research has an important message as we report a disappointingly low uptake — less than 1% — of infliximab’s biosimilars since first quarter of 2017.”